CRT PREDICTS | Stratified Randomization Study to Compare Different Duration of DAPT After Coronary Stenting in Either High or Low Bleeding Risk Populations

Sunday, March 9, 2025

10:00 AM - 10:20 AM ET

Moderator(s)

Gregg W. Stone, MD, FACC, MSCAI

Physician
Mount Sinai
New York, New York, United States

Disclosure information not submitted.
Ron Waksman, MD, MSCAI

Director, Cardiovascular Research and Advanced Education
MedStar Washington Hospital Center, MedStar Heart and Vascular Institute
Washington, District of Columbia, United States

Disclosure(s): Abbott Vascular: Grant/Research Support (Ongoing); Biotronik: Consultant (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corporation: Consultant (Ongoing), Grant/Research Support (Ongoing); Chiesi USA: Grant/Research Support (Ongoing)

Panel Discussant(s)

Paul A. Gurbel, MD, FSCAI

Director
Sinai Center for Thrombosis Research and Drug Development
Baltimore, Maryland, United States

Disclosure(s): No financial relationships to disclose
Adnan Kastrati, MD

Senior Consultant, Head of Catheterization Laboratory
Deutsches Herzzentrum Muenchen
Munich, Bayern, Germany

No relationships to disclose
Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI

Professor of Cardiology and Population Health Science and Policy, Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials; Director of Women’s Heart and Vascular Center at Mount Sinai Heart
Icahn School of Medicine at Mount Sinai, New York
New York, New York, United States

Disclosure information not submitted.

Disclosure(s):

Gregg W. Stone, MD, FACC, MSCAI: Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Vascular Dynamics, Pulnovo, V-wave: Research support to Mount Sinai Hospital (Ongoing); Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, RCE, Ablative Solutions, Abbott: Consultant (Terminated); Boehringer Ingelheim: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated); Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Shockwave, Biosense-Webster, Bioventrix: Research support to Mount Sinai Hospital (Terminated); Valfix, Zoll, HeartFlow, Shockwave, Ancora, Impulse Dynamics, Adona Medical, Oxitope, HighLife, Elixir, Elucid Bio, Aria, Alleviant, FBR Medical: Consultant (Ongoing)

Ron Waksman, MD, MSCAI: Abbott Vascular: Grant/Research Support (Ongoing); Biotronik: Consultant (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corporation: Consultant (Ongoing), Grant/Research Support (Ongoing); Chiesi USA: Grant/Research Support (Ongoing)